Posting of Circular and Notice of General Meeting

Oncimmune Holdings PLC

23 October 2024

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Posting of Circular and Notice of General Meeting

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, announces that, further to its announcement of 18 October 2024 containing details of the Fundraising and Debt Restructuring (the "Launch Announcement"), the Circular providing further details of the Fundraising and Debt Restructuring and convening the General Meeting has been posted to Shareholders today.

 

The Circular contains a notice of the General Meeting which is to be held at the offices of Cavendish Financial Plc, 1 Bartholomew Close, London EC1A 7BL, at 11:00 a.m. on 8 November 2024 to approve the resolutions required to, inter alia, implement the Fundraising and the Debt Restructuring.

 

The Circular and Form of Proxy (which will be sent to Shareholders along with the Circular) will also shortly be available on the Company's website www.oncimmune.com.

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Launch Announcement.

For further information:

Oncimmune Holdings plc

[e-mail]

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance) 

Nigel Birks, Life Science Specialist Sales

Ondraya Swanson (ECM)

[phone]

Zeus (Joint Broker)

Dominic King, Dan Bate

[phone]

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com

 

END